November 2022 Enforcement Scorecard: UDTs and Genetic Tests
Most of the recent settlements and enforcement actions involving labs related to medically unnecessary UDTs and genetic tests.
Most of the recent settlements and enforcement actions involving labs related to medically unnecessary UDTs and genetic tests.
In addition to the prison sentence for the x-ray-related fraud scheme, the company president must also pay nearly $2 million in restitution.
A recent $3.5 million settlement illustrates the kinds of pitfalls that can result in liability for hospital and freestanding sleep labs.
Recent case shows that fraud and kickback schemes involving CGx testing continue to be on the federal enforcement radar.
After the price transparency rules took effect in January 2021, CMS finally issued the first penalties for violations.